CTSO — Cytosorbents Corporation

Summary of CytoSorbents Corp. Q3 2025 Earnings Call

1. Key Financial Results and Metrics:

• Revenue: $9.5 million for Q3 2025, a 10% increase from $8.6 million in Q3 2024 (4% increase on a constant currency basis).
• Gross Margin: Improved to 70%, up from 61% in the prior year.
• Core Product Sales: Trailing 12-month sales reached a record $37 million, up from $33.8 million year-over-year.
• Operating Loss: Approximately $9.2 million, improved from $4.8 million in the prior year.
• Net Loss: $3.2 million or $0.05 per share, compared to a net loss of $2.8 million or $0.05 per share in Q3 2024.
• Adjusted Net Loss: Improved to $2.6 million or $0.04 per share, from $4.5 million or $0.08 per share in the prior year.
• Cash Position: $9.1 million as of September 30, down from $11.7 million at the end of Q2 2025, reflecting a net operating cash burn of $2.6 million.

2. Strategic Updates and Business Highlights:

• Core Business Growth: CytoSorb sales grew, particularly in distributor territories, while direct sales outside Germany rose 24%. However, sales in Germany declined by 3%.
• Product Pipeline: DrugSorb-ATR, aimed at managing perioperative bleeding, is on track for a new FDA submission in Q1 2026, following a pre-submission meeting request filed on November 7, 2025.
• Sales Team Restructuring: The company is restructuring its sales approach in Germany to improve performance, focusing on leadership, training, and targeting key accounts.
• Cost Management: Implemented a strategic workforce reduction of approximately 10% and other cost-cutting measures to achieve cash flow breakeven by Q1 2026.

3. Forward Guidance and Outlook:

• Regulatory Approval: Anticipates FDA decision on DrugSorb-ATR by mid-2026, with potential for expedited review.
• Sales Growth: Aims to return to higher growth in the CytoSorb business and achieve cash flow breakeven in early 2026.
• Improved Margins: Management expects continued improvement in gross margins as operational efficiencies are realized.

4. Bad News, Challenges, or Points of Concern:

• Decline in German Sales: Direct sales in Germany have seen a modest decline, prompting a restructuring of the sales team.
• Operating Losses: Despite improvements, the company continues to report significant operating losses and cash burn.
• Regulatory Hurdles: The FDA upheld the denial of the initial de novo submission for DrugSorb-ATR, necessitating a new submission process, which introduces uncertainty.

5. Notable Q&A Insights:

• Gross Margin Outlook: Management indicated that the 70% gross margin is expected to normalize, with potential for future improvements as efficiencies are realized.
• Sales Force Restructuring: While early metrics show improvements in sales rep performance, it is still a work in progress, and tangible sales growth in Germany is expected in future quarters.
• FDA Submission Clarification: The pre-submission meeting aims to align with FDA expectations and incorporate feedback into the final de novo application, which is crucial for successful approval.

Overall, CytoSorbents is making strides in its growth strategy, particularly with its core product sales and upcoming regulatory submissions, but faces challenges in the German market and ongoing financial losses.